Among them, the most common AE of olpasiran was injection site reaction (primarily pain).547 The Phase III trial of olpasiran aims to compare its effects with the placebo on the risk of coronary heart disease death, myocardial infarction, and urgent coronary revascularization in ASCVD patients with elevated Lp(a), with results expected by 2026 (NCT05581303). The gene discussed is LPA; the disease is atherosclerosis.